Lp-PLA2 et sPLA2 (Q58148425)

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Coronary artery disease prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Cytokines in atherosclerosis: pathogenic and regulatory pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Recent advances on the role of cytokines in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Biochemistry and physiology of mammalian secreted phospholipases A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Activation of human inflammatory cells by secreted phospholipases A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015

Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1051%2FMEDSCI%2F20143005015